Florian Stinauer

We are a tech company based in Münster, Germany, pioneering the chemical recycling of cotton-polyester textiles. Founded in 2019, we have developed a breakthrough technology that efficiently separates and recovers cellulose and PET monomers. These high-quality materials serve as the basis for virgin-quality fibers, enabling the transition toward a fully circular textile industry.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

Cellbox Solutions is a young technology company focusing on delivering innovative and new solutions for the correct handling of living cells and biologic structures. Our product Cellbox is a self-sustaining carbon dioxide incubator supporting the appropriate storage, reproduction, transportation and analysis of biologic materials. The incubator’s temperature and gas environment can be adjusted based on the biosphere necessary for the cultivating cells stored.

fasciotens is a dynamic medical device start-up founded by surgeons for surgeons with the goal of improving open abdomen therapy. Our first product fasciotens®Abdomen was intensively developed for new indications, so that today fasciotens®Hernia and fasciotens®Pediatric are available in addition to fasciotens®Abdomen. The innovative fasciotens products use a patented, tissue-sparing technique to apply vertical traction to the fasciae of the abdominal wall, thus creating the conditions for direct abdominal wall closure in cases of open abdomens, complex hernias as well as abdominal wall defects of newborns. For more information, please feel free to visit our website or contact us directly at info@fasciotens.de. We look forward to hearing from you!

Personal MedSystems is a pioneer in digital health. The company develops mobile diagnostic devices to enable the delivery of mobile healthcare. The CardioSecur product portfolio comprises mobile 12-lead ECG technologies that allow both patients and physicians to perform an instant heart check wherever they are. CardioSecur is the first and only mobile 22-lead ECG system with only 4 electrodes for physicians and patients. As easy to use personalized heart check for iPad/iPhone/iPod touch it enables patients at all times to gain certainty about their hearts‘ activity. Its instant evaluation of ischemic and rhythmic disorders and resulting direct recommendation allow patients to act swiftly and appropriately. Physicians do have the unique opportunity to perform precise diagnosis based on 22-lead ECG data from the moment of the cardiac event. So far an often insufficiently screened area.

As a Siemens Healthineers company, NEO New Oncology GmbH is a dynamically growing company offering complete solutions for molecular tumor profiling in cancer diagnostics and clinical research. NEO’s product range comprises streamlined assays, optimized bioinformatics, user friendly software for data interpretation and tailor made service packages enabling customers to provide meaningful results in a timely manner. NEO New Oncology is constantly optimizing its product portfolio and actively developing strong partnerships with pathologies, research institutes and industry.

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adenoviral vectors, Lentiviral vectors,), vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

We are a tech company based in Münster, Germany, pioneering the chemical recycling of cotton-polyester textiles. Founded in 2019, we have developed a breakthrough technology that efficiently separates and recovers cellulose and PET monomers. These high-quality materials serve as the basis for virgin-quality fibers, enabling the transition toward a fully circular textile industry.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

Cellbox Solutions is a young technology company focusing on delivering innovative and new solutions for the correct handling of living cells and biologic structures. Our product Cellbox is a self-sustaining carbon dioxide incubator supporting the appropriate storage, reproduction, transportation and analysis of biologic materials. The incubator’s temperature and gas environment can be adjusted based on the biosphere necessary for the cultivating cells stored.

fasciotens is a dynamic medical device start-up founded by surgeons for surgeons with the goal of improving open abdomen therapy. Our first product fasciotens®Abdomen was intensively developed for new indications, so that today fasciotens®Hernia and fasciotens®Pediatric are available in addition to fasciotens®Abdomen. The innovative fasciotens products use a patented, tissue-sparing technique to apply vertical traction to the fasciae of the abdominal wall, thus creating the conditions for direct abdominal wall closure in cases of open abdomens, complex hernias as well as abdominal wall defects of newborns. For more information, please feel free to visit our website or contact us directly at info@fasciotens.de. We look forward to hearing from you!

The focus of the company is the development, demonstration of clinical benefit, and early-stage commercialization of cryotherapy systems for the treatment of coronary plaque.